Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7305014 | 1.00 | GID4 (0.54) | GID4DDB1CRBNKDM4EALDH1A1 | |
| SCHEMBL7318408 | 0.82 | ALDH1A1 (0.46) | DDB1CRBNKDM4EALDH1A1MEN1 | |
| SCHEMBL7318404 | 0.82 | ALDH1A1 (0.46) | DDB1CRBNKDM4EALDH1A1MEN1 | |
| SCHEMBL182434 | 0.78 | DDB1 (0.58) | GID4DDB1CRBNHTR2CMEN1 | |
| SCHEMBL4128714 | 0.77 | DDB1 (0.57) | GID4DDB1CRBNHTR2CMEN1 | |
| SCHEMBL1201856 | 0.77 | ALDH1A1 (0.59) | DDB1CRBNKDM4EALDH1A1MEN1 | |
| SCHEMBL15874872 | 0.77 | ALDH1A1 (0.59) | DDB1CRBNKDM4EALDH1A1MEN1 | |
| SCHEMBL1201854 | 0.77 | ALDH1A1 (0.59) | DDB1CRBNKDM4EALDH1A1MEN1 | |
| Water SCHEMBL8222140 | 0.76 | ALDH1A1 (0.58) | DDB1CRBNKDM4EALDH1A1MEN1 | |
| SCHEMBL29497128 | 0.76 | ALDH1A1 (0.58) | DDB1CRBNKDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | MERCK & CO., INC. | 2002-03-28 | — | — | US | disclosed |
| US-6284755-B1 | Inhibitors of prenyl-protein transferase | MERCK & CO., INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000034437-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037888-A1 | 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease | FNTA, PKD1, FNTB | GID4 364/4885DDB1 408/4885CRBN 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.